Toimitusprosessi maanrakennuksen näkökulmasta

Tämä insinöörityö tehtiin Eltel Networks Oy:n Tele-etelän alueyksikölle. Tässä työssä tutkittiin Eltel Networks Oy:n toimitusprosessia maanrakennuksen näkökulmasta. Paneuduttiin toimitusprosessin ongelmakohtiin ja pyrittiin kehittämään koko toimitusprosessia. Tarkemmassa kuvauksessa oli suunnittelu, maanrakentaminen, toimitusprosessi ja sen pohjalta tehdyt prosessikaaviot sekä toimittajaporttaali. Lopputulema ja kehitysehdotukset toiminnan parantamiseksi esitetään viimeisessä luvussa tarkemmin. Kehitysehdotuksina toimitusprosessin parantamiseksi saatiin toisten osapuolten kanssa aktiivinen ja tiiviimpi toimiminen ja yhteistyö. Urakoitsijoiden valitsemisen vaikutus kustannustehokkuuteen ja siihen kiinnitettävän huomion tärkeys. Lisäksi kehitysehdotuksena on tytäryhtiön perustaminen, joka vastaisi kaikesta maanrakennuksesta yrityksessä.This thesis was made for Eltel Networks Oy. The main subject of this thesis is to inspect the delivery process from the point of view of earth-moving. There were three main points in the inspection such as planning, earth-moving and overhead sign support. In this thesis the whole delivery process was investigated from the point of view of earth-moving and also the problems related to it. One of the aims of this thesis has also been to create a more effective delivery process. The results are in view at the end of this thesis. As a development suggestion to the delivery process, more liaison with other companies who are working in the same area is recommended. Also, selecting the contractor is very important to get the best cost effectiveness

Sparse and Constrained Stochastic Predictive Control for Networked Systems

This article presents a novel class of control policies for networked control of Lyapunov-stable linear systems with bounded inputs. The control channel is assumed to have i.i.d. Bernoulli packet dropouts and the system is assumed to be affected by additive stochastic noise. Our proposed class of policies is affine in the past dropouts and saturated values of the past disturbances. We further consider a regularization term in a quadratic performance index to promote sparsity in control. We demonstrate how to augment the underlying optimization problem with a constant negative drift constraint to ensure mean-square boundedness of the closed-loop states, yielding a convex quadratic program to be solved periodically online. The states of the closed-loop plant under the receding horizon implementation of the proposed class of policies are mean square bounded for any positive bound on the control and any non-zero probability of successful transmission

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE.

BACKGROUND: Data regarding the effectiveness of anti-tumor necrosis factor (TNF) agents for resolution of extraintestinal manifestations (EIMs) are scarce. The CARE study evaluated clinical effectiveness, EIM resolution, and safety of adalimumab in a large pan-European cohort of patients with moderate to severe Crohn's disease (CD). METHODS: In all, 945 patients with a Harvey-Bradshaw Index (HBI) >/=7 enrolled in this multicenter, open-label phase IIIb trial. Patients received subcutaneous adalimumab, 160/80 mg at weeks 0/2, then 40 mg every other week. Dose adjustments were allowed for CD-related concomitant medications (from week 8) and adalimumab (from week 12). Clinical endpoints were analyzed through week 20 for all patients, and after stratification by prior infliximab exposure and by reason for discontinuing infliximab (primary nonresponse [PNR] or other). RESULTS: The remission rate (HBI <5) at week 20 was 52% (95% confidence interval, 49%-55%) overall, and was higher for infliximab-naive versus infliximab-exposed patients (62% versus 42%, P < 0.001). Remission rates were similar for PNR (37%) and other reasons (43%; P = 0.278). Of 497 patients with baseline EIMs, 51% were free of EIM signs and symptoms at week 20. Serious infectious adverse events were reported in 5% of patients. Opportunistic infections and malignancies were rare (</=1%). There was one case of demyelinating disease, but no occurrences of lupus, tuberculosis, or death. CONCLUSIONS: In this large cohort of patients, adalimumab treatment resulted in rates of clinical remission and EIM resolution exceeding 50%, and substantial rates of effectiveness in patients who had PNR to infliximab. Adalimumab was well tolerated, with safety consistent with prior reports. (Inflamm Bowel Dis 2011)